You are here

Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Aalborg Universitetshospital Nord/Reumatologisk Afdelning
Aalborg, , 9000 Denmark
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis (RA)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject fulfils criteria for Rheumatoid Arthritis (RA) according to ACR or EULAR
criteria.

- Subjects who are planned to start treatment with ADA, ETA, CER or IFX

- Subjects taking a minimum weekly dose of 7.5 mg of methotrexate

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with compliance problems

- Patients who have difficulties in reading and understanding local language

- Patients with Juvenile Idiopathic Arthritis (JIA)

- Azathioprine or cyclophosphamide treatment within 6 months before entering into the
study

NCT01691014
Pfizer
Terminated
Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now